Corbus Receives FDA Fast-Track Designation for Head and Neck Cancer Drug

Corbus Pharmaceuticals has received FDA fast-track designation for its head and neck cancer drug. The company's pipeline includes CRB-701, an antibody drug conjugate targeting Nectin-4 on cancer cells, and CRB-601, an anti-integrin monoclonal antibody blocking TGFβ expression on cancer cells. Additionally, the company has in-licensed CRB-601 from the University of California, San Francisco, and is developing CRB-913, a cannabinoid type-1 receptor inverse agonist for obesity treatment.